Literature DB >> 30599101

MRI Brain Signal Intensity and Relaxation Times in Individuals with Prior Exposure to Gadobutrol.

Marc Saake1, Alexandra Schmidle1, Markus Kopp1, Jannis Hanspach1, Tobias Hepp1, Frederik B Laun1, Armin M Nagel1, Arnd Dörfler1, Michael Uder1, Tobias Bäuerle1.   

Abstract

Purpose To perform follow-up brain MRI in volunteer participants who had previously received multiple doses of gadobutrol and to assess for changes in signal intensities and relaxation times. Materials and Methods This prospective study included 160 participants who received gadobutrol only between 2007 and 2017. The participants were separated into two groups, including participants with at least five contrast agent-enhanced examinations and normal kidney function (group 1) or at least one examination and impaired renal function (group 2). Control groups with normal and impaired renal function (groups 3 and 4) without history of contrast agent exposure were included for comparison. Unenhanced brain MRI was performed in 220 participants (76, 84, 25, and 35 participants in groups 1-4, respectively) with T1-weighted spin-echo and T1 and T2 mapping to determine visual signal intensity changes, signal intensity ratios (globus pallidus-to-thalamus and dentate nucleus-to-pons ratios), and T1 and T2 relaxation times. Results In groups 1 and 2, neither visual signal alterations nor differences in signal intensity ratio or T2 mapping were found. T1 mapping showed no changes for dentate nucleus, pons, and thalamus. However, shorter T1 relaxation times in the globus pallidus were found in group 1 compared with group 3 (difference of -26.2 msec; P = .002), which correlated with the number of previous gadobutrol doses in this group (P = .001). Conclusion In study participants who had previously received gadobutrol, brain MRI showed no differences relative to healthy control participants without gadobutrol exposure. However, quantitative T1 measurements might indicate gadolinium retention in the globus pallidus. © RSNA, 2018 Online supplemental material is available for this article.

Entities:  

Year:  2019        PMID: 30599101     DOI: 10.1148/radiol.2018181927

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Impact of Kidney Function on CNS Gadolinium Deposition in Patients Receiving Repeated Doses of Gadobutrol.

Authors:  S Dogra; M J Borja; Y W Lui
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-25       Impact factor: 3.825

2.  MR Fingerprinting-A Radiogenomic Marker for Diffuse Gliomas.

Authors:  Elisabeth Springer; Pedro Lima Cardoso; Bernhard Strasser; Wolfgang Bogner; Matthias Preusser; Georg Widhalm; Mathias Nittka; Gregor Koerzdoerfer; Pavol Szomolanyi; Gilbert Hangel; Johannes A Hainfellner; Wolfgang Marik; Siegfried Trattnig
Journal:  Cancers (Basel)       Date:  2022-01-30       Impact factor: 6.575

3.  Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging.

Authors:  Kathrin Barbara Krug; Christina Jane Burke; Kilian Weiss; Pascal A T Baltzer; Kerstin Rhiem; David Maintz; Marc Schlamann; Martin Hellmich
Journal:  Eur Radiol       Date:  2021-07-03       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.